[0001]

This invention relates to colorectal cancer including the miRNA expression amount measuring Kit for detection of nucleic acid that can be merged in the singular and specific miRNA in the subjects used to test for the presence or absence of disease to colorectal cancer, including colorectal cancer or devices, and the nucleic acid detection methods.

His innovations.

[0002]

Colon's organ absorbs the moisture to the stool, bowel contents were digested and absorbed the remaining accumulated. Followed by a colon, cecum begins on connected to the ascending colon, transverse colon, descending colon, sigmoid colon, rectum and anus tube. National Research Development Corporation National Cancer Research Center for cancer statistics of cancer in Japan to disclose information center 2011 colorectal cancer, according to cancer colorectal cancer incidence by number is 112772, that about 14 people in the Japanese one, and population no. 2 cancer site. Also is the number of deaths from colorectal cancer men and women together 45744 people up to the number of deaths # 3 cancer site. Also, also in the United States, to about 20 people at the rate of one cause colon cancer said, in 2014 in the United States estimated colorectal cancer the incidence of fatality about 40000 people, 96830 people (non-patent literature 1).

[0003]

Colorectal cancer progression is provided for non-patent literature 2 tumor spread (Tis, T1-T4), lymph nodes (N0, N1a-c, N2a-b), distant metastases (M0, M1a-b) of stage I, stage 0 (Tis/N0/M0), depending on (T1-T2/N0/M0), stage II (T3-T4/N0/M0), (T3/N0/M0) stage IIA, stage IIB (T4a/N0/M0) and stage IIC (T4b/N0/M0), stage III (N1-2 / M0), Stage IIIA (T1-2 / N1 / M0 and T1/N2a/M0), stage IIIB (T3-T4a/N1/M0 and T2-T3/N2a/M0 and T1 ~ T2/N2b/M0), stage IIIC (T4a/N2a/M0 and T3-T4a/N2b/M0 and T4b/N1-2 / M0), classified in stage IVA (M1a), stage IVB (M1b).

[0004]

Depending on advanced colorectal cancer survival, 1 non-patent literature is divided into colon cancer and rectal cancer following statistics have been reported. Colon cancer 5-year relative survival rate, 74% of stage I, 67% of stage IIA, 59% of stage IIB, 37% of stage IIC 73% are stage IIIA, stage IIIB, 46% have been reported with stage IIIC is 28%, and 6% are stage IV. Also, colorectal cancer five-year relative survival rate is, 74% of stage I, 65% of stage IIA stage IIB is 52%, 32% stage IIC, 74% are stage IIIA, stage IIIB, 45% have been reported with stage IIIC is 33%, and 6% are stage IV. From more than the slow progression from colorectal cancer survival rate is high. So the contribution to improve the survival rate of colon cancer found early in the treatment.

[0005]

Combined anticancer chemotherapy and radiation treatment after surgery, colon cancer treatment is primarily an open surgery or laparoscopic surgery and many (non-patent literature 1). There is able to adapt can be treated without surgery in the early stage of colorectal cancer, especially in endoscopic surgery.

[0006]

As described in the non-patent literature 1, test for colon cancer, colonoscopy, fecal occult blood test widely. Especially fecal occult blood tests are inexpensive and non-invasive and noninvasive, carried out at home because the United States Cancer Association recommends to undergo fecal occult blood test every year. To examine the cancer area and spread, in addition to the colonoscopy, barium enema, computed tomography and imaging procedures such as MRI to be executed. In addition, purposes and observation on prognosis and therapeutic effect observation for patients with colorectal cancer have been diagnosed already, carried out the blood tumor marker CEA and ca19-9 may (non-patent literature 1).

[0007]

In the research phase, patent literature 1-is reported to detect colorectal cancer by combination of micro RNA (miRNA) is shown in 4 on blood and other biological samples in gene or miRNA gene and expression of protein markers for others and.

[0008]

In the patent literature 1 colorectal cancer has been shown to detect colon cancer and other cancers using in hsa-miR-92a-2-5p, hsa-miR-128-2-5p, and hsa-miR-24-3p.

[0009]

How to detect colorectal cancer using plasma hsa-miR-1233-5p and hsa-miR-1225-3p in the patent literature 2 has been shown.

[0010]

Includes how to detect colorectal cancer using fecal and colonic tissue hsa-miR-1231, hsa-miR-423-5p, hsa-miR-, 1268 a multiple of miRNA in the patent literature 3.

[0011]

How to detect colorectal cancer in hsa-miR-150-3p and miR-92a-2-5p in the patent literature 4 has been shown.

Prior art documents

Patent documents

[0012]

Patent literature 1: international publication No. 2007 / 081740,
Patent literature 2: United States patent application publication No. 2013 / 102487 item specification
Patent literature 3: United States patent application publication No. 2012 / 088687 of specification
Patent literature 4: advanced table 2009-531019 of public information

Non-patent literature

[0013]

Non-patent literature 1: American Cancer Society "Colorectal Cancer", supervised by 2013, p. 5-6, 17-28, 33-and 45-54, 67-71
Non-patent literature 2: Sobin, l. The TNM Classification of Malignant Tumours, 7th Edition 2010, p. 94-99
Non-patent literature 3: Allison and JE... From 1996, The New England Journal of Medicine, no. 334 (3), p. 155-9
Non-patent literature 4: Palmqvist, R. From 2007, the Diseases of colon and rectum, no. 46 (11), p. 1538-44

Summary of the invention

Inventors are trying to solve a problem

[0014]

Challenges of the present invention is a new colorectal cancer to offer ways you can effectively detect colorectal cancer using the heading marker, said marker specifically binding DNA. Cannot detect colorectal cancer do not bleed while they are judged to be positive even if the fecal occult blood test as preliminary tests for colorectal cancer currently widespread, on why it is not cancer, such as hemorrhoids bleeding early, Miss (including cancer) colon abnormalities in more than 90 percent reported some (non-patent literature 1). Sensitivity fecal occult blood testing and specifically the test kit to use 37 %~79. 4 percent very different, also, specificity 86. 7 %~97. 7 percent and the (non-patent literature 3). Also known high quality of colonoscopy, but need for treatment or sedative, higher prices from primary screening apply to and hard to (non-patent literature 1). Is said to determine the presence of colorectal cancer due to rise in cancers other than colon cancer serum tumor markers CEA and ca19-9 is not. Will force the economic and physical burden on patients by applying wrong and discontinuing treatment appropriate to diagnose colorectal cancer and other cancers, and medical care. For this reason, CEA and ca19-9 observation on prognosis of the patients already diagnosed with colorectal cancer and therapeutic effects observation on limited use tend to be (non-patent literature 1). In CEA test specificity was 99%, according to the report, while sensitivity is only 12 percent without the colon cancer has been the significance of tumor marker measurement as a screening test and (non-patent document 4).

[0015]

Reports also determine colorectal cancer using mRNA is in the research stage blood and other biological samples in micro RNA (miRNA) that have shown below, but none yet practical.

[0016]

In the patent literature 1 colorectal cancer has been shown to detect colon cancer and other cancers using in HSY-Mir-92y-2-5p, HSY-Mir-128-2-5p, and HSY-Mir-24-3p. Must however this detection method is to obtain tissue of colorectal cancer surgery and a heavy physical burdens of patients with this stage testing approach is not desirable. Also, for this detection method is not stated on the detection performance of colorectal cancer, such as specific accuracy, sensitivity and specificity for the industrial development of scarce.

[0017]

Includes how to detect colorectal cancer using miRNA colon tissue or stool in HSY-Mir-1231, HSY-Mir-423-5p, HSY-Mir-, 1268 a multiple of patent documents 3. But with colon cancer, while heavy physical burdens on the patient to surgery in order to get the Organization to test approach is undesirable. Also, although that stool samples are non-invasive noninvasive sampling in subject material exists uniformly crap in, inspection results and prone variation there.

[0018]

Have shown how to detect colorectal cancer in hsa-miR-150-3p and miR-92a-2-5p in the patent literature 4, but mentioned for accuracy, precision, sensitivity, specificity, also does not include colorectal cancer using specific blood detection method for weak industrial utility. To further the above miRNA marker cannot be validated in an independent sample group, cannot be trusted.

[0019]

If using them for, so detection of colorectal cancer, tumor marker for existing performance low, also on the marker of how performance and detection specifically does not contain a Ken yomimasu colorectal cancer useless additional inspection due to false positives with patients, or colorectal cancer there is possibility of lost treatment opportunity by overlooking the patient. In addition, several dozen-difficult to use large scale screening for increased inspection costs measure the miRNA consisting of several hundred pieces of health such as. Also taking colon tissue to measure tumor markers is to give patients less invasive and undesirable for the low allows detection of blood samples can be invasive, colorectal cancer patients with colorectal cancer colon cancer patients and Ken yomimasu Ken yomimasu and correctly identify the precise marker is required. Colorectal cancer is found early, treatment, can greatly improve the survival rate. In addition, high-sensitivity from endoscopic surgery to treat without surgery if colon cancer, if caught early can be adapted to detect even low-stage colorectal cancer colon cancer markers are coveted.

Means for resolving problems

[0020]

To resolve the above issues inventors as a result of the study low reached the finding that can detect colon cancer significantly by using this a possible binding to specific DNA heading markers for colorectal cancer detection can be used with more than one gene from blood samples can be invasive, to perfect the invention.

[0021]

Summary of the invention
Namely, the invention has the following features.
（１）大腸がんマーカーである、ｍｉＲ－６７２６－５ｐ、ｍｉＲ－４２５７、ｍｉＲ－６７８７－５ｐ、ｍｉＲ－６７８０ｂ－５ｐ、ｍｉＲ－３１３１、ｍｉＲ－７１０８－５ｐ、ｍｉＲ－１３４３－３ｐ、ｍｉＲ－１２４７－３ｐ、ｍｉＲ－４６５１、ｍｉＲ－６７５７－５ｐ、ｍｉＲ－３６７９－５ｐ、ｍｉＲ－７６４１、ｍｉＲ－６７４６－５ｐ、ｍｉＲ－８０７２、ｍｉＲ－６７４１－５ｐ、ｍｉＲ－１９０８－５ｐ、ｍｉＲ－６８５７－５ｐ、ｍｉＲ－４７４６－３ｐ、ｍｉＲ－７４４－５ｐ、ｍｉＲ－４７９２、ｍｉＲ－５６４、ｍｉＲ－６７９１－５ｐ、ｍｉＲ－６８２５－５ｐ、ｍｉＲ－６８２６－５ｐ、ｍｉＲ－４６６５－３ｐ、ｍｉＲ－４４６７、ｍｉＲ－３１８８、ｍｉＲ－６１２５、ｍｉＲ－６７５６－５ｐ、ｍｉＲ－１２２８－３ｐ、ｍｉＲ－８０６３、ｍｉＲ－８０６９、ｍｉＲ－６８７５－５ｐ、ｍｉＲ－３１８５、ｍｉＲ－４４３３ｂ－３ｐ、ｍｉＲ－６８８７－５ｐ、ｍｉＲ－１２８－１－５ｐ、ｍｉＲ－６７２４－５ｐ、ｍｉＲ－１９１４－３ｐ、ｍｉＲ－１２２５－５ｐ、ｍｉＲ－４４１９ｂ、ｍｉＲ－７１１０－５ｐ、ｍｉＲ－１８７－５ｐ、ｍｉＲ－３１８４－５ｐ、ｍｉＲ－２０４－３ｐ、ｍｉＲ－５５７２、ｍｉＲ－６７２９－５ｐ、ｍｉＲ－６１５－５ｐ、ｍｉＲ－６７４９－５ｐ、ｍｉＲ－６５１５－３ｐ、ｍｉＲ－３９３７、ｍｉＲ－６８４０－３ｐ、ｍｉＲ－６８９３－５ｐ、ｍｉＲ－４７２８－５ｐ、ｍｉＲ－６７１７－５ｐ、ｍｉＲ－７１１３－３ｐ、ｍｉＲ－４６６５－５ｐ、ｍｉＲ－６４２ｂ－３ｐ、ｍｉＲ－７１０９－５ｐ、ｍｉＲ－６８４２－５ｐ、ｍｉＲ－４４４２、ｍｉＲ－４４３３－３ｐ、ｍｉＲ－４７０７－５ｐ、ｍｉＲ－６１２６、ｍｉＲ－４４４９、ｍｉＲ－４７０６、ｍｉＲ－１９１３、ｍｉＲ－６０２、ｍｉＲ－９３９－５ｐ、ｍｉＲ－４６９５－５ｐ、ｍｉＲ－７１１、ｍｉＲ－６８１６－５ｐ、ｍｉＲ－４６３２－５ｐ、ｍｉＲ－６７２１－５ｐ、ｍｉＲ－７８４７－３ｐ、ｍｉＲ－６１３２、ｍｉＲ－８８７－３ｐ、ｍｉＲ－３６７９－３ｐ、ｍｉＲ－６７８４－５ｐ、ｍｉＲ－１２４９、ｍｉＲ－９３７－５ｐ、ｍｉＲ－５１９５－３ｐ、ｍｉＲ－６７３２－５ｐ、ｍｉＲ－４４１７、ｍｉＲ－４２８１、ｍｉＲ－４７３４、ｍｉＲ－６７６６－３ｐ、ｍｉＲ－６６３ａ、ｍｉＲ－４５１３、ｍｉＲ－６７８１－５ｐ、ｍｉＲ－１２２７－５ｐ、ｍｉＲ－６８４５－５ｐ、ｍｉＲ－６７９８－５ｐ、ｍｉＲ－３６２０－５ｐ、ｍｉＲ－１９１５－５ｐ、ｍｉＲ－４２９４、ｍｉＲ－６４２ａ－３ｐ、ｍｉＲ－３７１ａ－５ｐ、ｍｉＲ－９４０、ｍｉＲ－４４５０、ｍｉＲ－４７２３－５ｐ、ｍｉＲ－１４６９、ｍｉＲ－６８６１－５ｐ、ｍｉＲ－７９７５、ｍｉＲ－６８７９－５ｐ、ｍｉＲ－６８０２－５ｐ、ｍｉＲ－１２６８ｂ、ｍｉＲ－６６３ｂ、ｍｉＲ－１２５ａ－３ｐ、ｍｉＲ－２８６１、ｍｉＲ－６０８８、ｍｉＲ－４７５８－５ｐ、ｍｉＲ－２９６－３ｐ、ｍｉＲ－６７３８－５ｐ、ｍｉＲ－６７１－５ｐ、ｍｉＲ－４４５４、ｍｉＲ－４５１６、ｍｉＲ－７８４５－５ｐ、ｍｉＲ－４７４１、ｍｉＲ－９２ｂ－５ｐ、ｍｉＲ－６７９５－５ｐ、ｍｉＲ－６８０５－３ｐ、ｍｉＲ－４７２５－３ｐ、ｍｉＲ－６７８２－５ｐ、ｍｉＲ－４６８８、ｍｉＲ－６８５０－５ｐ、ｍｉＲ－６７７７－５ｐ、ｍｉＲ－６７８５－５ｐ、ｍｉＲ－７１０６－５ｐ、ｍｉＲ－３６６３－３ｐ、ｍｉＲ－６１３１、ｍｉＲ－１９１５－３ｐ、ｍｉＲ－４５３２、ｍｉＲ－６８２０－５ｐ、ｍｉＲ－４６８９、ｍｉＲ－４６３８－５ｐ、ｍｉＲ－３６５６、ｍｉＲ－３６２１、ｍｉＲ－６７６９ｂ－５ｐ、ｍｉＲ－１４９－３ｐ、ｍｉＲ－２３ｂ－３ｐ、ｍｉＲ－３１３５ｂ、ｍｉＲ－６８４８－５ｐ、ｍｉＲ－６７６９ａ－５ｐ、ｍｉＲ－４３２７、ｍｉＲ－６７６５－３ｐ、ｍｉＲ－６７１６－５ｐ、ｍｉＲ－６８７７－５ｐ、ｍｉＲ－６７２７－５ｐ、ｍｉＲ－４５３４、ｍｉＲ－６１４、ｍｉＲ－１２０２、ｍｉＲ－５７５、ｍｉＲ－６８７０－５ｐ、ｍｉＲ－６７２２－３ｐ、ｍｉＲ－７９７７、ｍｉＲ－４６４９－５ｐ、ｍｉＲ－４６７５、ｍｉＲ－６０７５、ｍｉＲ－６７７９－５ｐ、ｍｉＲ－４２７１、ｍｉＲ－３１９６、ｍｉＲ－６８０３－５ｐ、ｍｉＲ－６７８９－５ｐ、ｍｉＲ－４６４８、ｍｉＲ－４５０８、ｍｉＲ－４７４９－５ｐ、ｍｉＲ－４５０５、ｍｉＲ－５６９８、ｍｉＲ－１１９９－５ｐ、ｍｉＲ－４７６３－３ｐ、ｍｉＲ－６８３６－３ｐ、ｍｉＲ－３１９５、ｍｉＲ－７１８、ｍｉＲ－３１７８、ｍｉＲ－６３８、ｍｉＲ－４４９７、ｍｉＲ－６０８５、ｍｉＲ－６７５２－５ｐ及びｍｉＲ－１３５ａ－３ｐからなる群から選択される少なくとも１つ以上のポリヌクレオチドと特異的に結合可能な核酸を含む、大腸がんの検出用キット。

[0022]

（２）ｍｉＲ－６７２６－５ｐがｈｓａ－ｍｉＲ－６７２６－５ｐであり、ｍｉＲ－４２５７がｈｓａ－ｍｉＲ－４２５７であり、ｍｉＲ－６７８７－５ｐがｈｓａ－ｍｉＲ－６７８７－５ｐであり、ｍｉＲ－６７８０ｂ－５ｐがｈｓａ－ｍｉＲ－６７８０ｂ－５ｐであり、ｍｉＲ－３１３１がｈｓａ－ｍｉＲ－３１３１であり、ｍｉＲ－７１０８－５ｐがｈｓａ－ｍｉＲ－７１０８－５ｐであり、ｍｉＲ－１３４３－３ｐがｈｓａ－ｍｉＲ－１３４３－３ｐであり、ｍｉＲ－１２４７－３ｐがｈｓａ－ｍｉＲ－１２４７－３ｐであり、ｍｉＲ－４６５１がｈｓａ－ｍｉＲ－４６５１であり、ｍｉＲ－６７５７－５ｐがｈｓａ－ｍｉＲ－６７５７－５ｐであり、ｍｉＲ－３６７９－５ｐがｈｓａ－ｍｉＲ－３６７９－５ｐであり、ｍｉＲ－７６４１がｈｓａ－ｍｉＲ－７６４１であり、ｍｉＲ－６７４６－５ｐがｈｓａ－ｍｉＲ－６７４６－５ｐであり、ｍｉＲ－８０７２がｈｓａ－ｍｉＲ－８０７２であり、ｍｉＲ－６７４１－５ｐがｈｓａ－ｍｉＲ－６７４１－５ｐであり、ｍｉＲ－１９０８－５ｐがｈｓａ－ｍｉＲ－１９０８－５ｐであり、ｍｉＲ－６８５７－５ｐがｈｓａ－ｍｉＲ－６８５７－５ｐであり、ｍｉＲ－４７４６－３ｐがｈｓａ－ｍｉＲ－４７４６－３ｐであり、ｍｉＲ－７４４－５ｐがｈｓａ－ｍｉＲ－７４４－５ｐであり、ｍｉＲ－４７９２がｈｓａ－ｍｉＲ－４７９２であり、ｍｉＲ－５６４がｈｓａ－ｍｉＲ－５６４であり、ｍｉＲ－６７９１－５ｐがｈｓａ－ｍｉＲ－６７９１－５ｐであり、ｍｉＲ－６８２５－５ｐがｈｓａ－ｍｉＲ－６８２５－５ｐであり、ｍｉＲ－６８２６－５ｐがｈｓａ－ｍｉＲ－６８２６－５ｐであり、ｍｉＲ－４６６５－３ｐがｈｓａ－ｍｉＲ－４６６５－３ｐであり、ｍｉＲ－４４６７がｈｓａ－ｍｉＲ－４４６７であり、ｍｉＲ－３１８８がｈｓａ－ｍｉＲ－３１８８であり、ｍｉＲ－６１２５がｈｓａ－ｍｉＲ－６１２５であり、ｍｉＲ－６７５６－５ｐがｈｓａ－ｍｉＲ－６７５６－５ｐであり、ｍｉＲ－１２２８－３ｐがｈｓａ－ｍｉＲ－１２２８－３ｐであり、ｍｉＲ－８０６３がｈｓａ－ｍｉＲ－８０６３であり、ｍｉＲ－８０６９がｈｓａ－ｍｉＲ－８０６９であり、ｍｉＲ－６８７５－５ｐがｈｓａ－ｍｉＲ－６８７５－５ｐであり、ｍｉＲ－３１８５がｈｓａ－ｍｉＲ－３１８５であり、ｍｉＲ－４４３３ｂ－３ｐがｈｓａ－ｍｉＲ－４４３３ｂ－３ｐであり、ｍｉＲ－６８８７－５ｐがｈｓａ－ｍｉＲ－６８８７－５ｐであり、ｍｉＲ－１２８－１－５ｐがｈｓａ－ｍｉＲ－１２８－１－５ｐであり、ｍｉＲ－６７２４－５ｐがｈｓａ－ｍｉＲ－６７２４－５ｐであり、ｍｉＲ－１９１４－３ｐがｈｓａ－ｍｉＲ－１９１４－３ｐであり、ｍｉＲ－１２２５－５ｐがｈｓａ－ｍｉＲ－１２２５－５ｐであり、ｍｉＲ－４４１９ｂがｈｓａ－ｍｉＲ－４４１９ｂであり、ｍｉＲ－７１１０－５ｐがｈｓａ－ｍｉＲ－７１１０－５ｐであり、ｍｉＲ－１８７－５ｐがｈｓａ－ｍｉＲ－１８７－５ｐであり、ｍｉＲ－３１８４－５ｐがｈｓａ－ｍｉＲ－３１８４－５ｐであり、ｍｉＲ－２０４－３ｐがｈｓａ－ｍｉＲ－２０４－３ｐであり、ｍｉＲ－５５７２がｈｓａ－ｍｉＲ－５５７２であり、ｍｉＲ－６７２９－５ｐがｈｓａ－ｍｉＲ－６７２９－５ｐであり、ｍｉＲ－６１５－５ｐがｈｓａ－ｍｉＲ－６１５－５ｐであり、ｍｉＲ－６７４９－５ｐがｈｓａ－ｍｉＲ－６７４９－５ｐであり、ｍｉＲ－６５１５－３ｐがｈｓａ－ｍｉＲ－６５１５－３ｐであり、ｍｉＲ－３９３７がｈｓａ－ｍｉＲ－３９３７であり、ｍｉＲ－６８４０－３ｐがｈｓａ－ｍｉＲ－６８４０－３ｐであり、ｍｉＲ－６８９３－５ｐがｈｓａ－ｍｉＲ－６８９３－５ｐであり、ｍｉＲ－４７２８－５ｐがｈｓａ－ｍｉＲ－４７２８－５ｐであり、ｍｉＲ－６７１７－５ｐがｈｓａ－ｍｉＲ－６７１７－５ｐであり、ｍｉＲ－７１１３－３ｐがｈｓａ－ｍｉＲ－７１１３－３ｐであり、ｍｉＲ－４６６５－５ｐがｈｓａ－ｍｉＲ－４６６５－５ｐであり、ｍｉＲ－６４２ｂ－３ｐがｈｓａ－ｍｉＲ－６４２ｂ－３ｐであり、ｍｉＲ－７１０９－５ｐがｈｓａ－ｍｉＲ－７１０９－５ｐであり、ｍｉＲ－６８４２－５ｐがｈｓａ－ｍｉＲ－６８４２－５ｐであり、ｍｉＲ－４４４２がｈｓａ－ｍｉＲ－４４４２であり、ｍｉＲ－４４３３－３ｐがｈｓａ－ｍｉＲ－４４３３－３ｐであり、ｍｉＲ－４７０７－５ｐがｈｓａ－ｍｉＲ－４７０７－５ｐであり、ｍｉＲ－６１２６がｈｓａ－ｍｉＲ－６１２６であり、ｍｉＲ－４４４９がｈｓａ－ｍｉＲ－４４４９であり、ｍｉＲ－４７０６がｈｓａ－ｍｉＲ－４７０６であり、ｍｉＲ－１９１３がｈｓａ－ｍｉＲ－１９１３であり、ｍｉＲ－６０２がｈｓａ－ｍｉＲ－６０２であり、ｍｉＲ－９３９－５ｐがｈｓａ－ｍｉＲ－９３９－５ｐであり、ｍｉＲ－４６９５－５ｐがｈｓａ－ｍｉＲ－４６９５－５ｐであり、ｍｉＲ－７１１がｈｓａ－ｍｉＲ－７１１であり、ｍｉＲ－６８１６－５ｐがｈｓａ－ｍｉＲ－６８１６－５ｐであり、ｍｉＲ－４６３２－５ｐがｈｓａ－ｍｉＲ－４６３２－５ｐであり、ｍｉＲ－６７２１－５ｐがｈｓａ－ｍｉＲ－６７２１－５ｐであり、ｍｉＲ－７８４７－３ｐがｈｓａ－ｍｉＲ－７８４７－３ｐであり、ｍｉＲ－６１３２がｈｓａ－ｍｉＲ－６１３２であり、ｍｉＲ－８８７－３ｐがｈｓａ－ｍｉＲ－８８７－３ｐであり、ｍｉＲ－３６７９－３ｐがｈｓａ－ｍｉＲ－３６７９－３ｐであり、ｍｉＲ－６７８４－５ｐがｈｓａ－ｍｉＲ－６７８４－５ｐであり、ｍｉＲ－１２４９がｈｓａ－ｍｉＲ－１２４９であり、ｍｉＲ－９３７－５ｐがｈｓａ－ｍｉＲ－９３７－５ｐであり、ｍｉＲ－５１９５－３ｐがｈｓａ－ｍｉＲ－５１９５－３ｐであり、ｍｉＲ－６７３２－５ｐがｈｓａ－ｍｉＲ－６７３２－５ｐであり、ｍｉＲ－４４１７がｈｓａ－ｍｉＲ－４４１７であり、ｍｉＲ－４２８１がｈｓａ－ｍｉＲ－４２８１であり、ｍｉＲ－４７３４がｈｓａ－ｍｉＲ－４７３４であり、ｍｉＲ－６７６６－３ｐがｈｓａ－ｍｉＲ－６７６６－３ｐであり、ｍｉＲ－６６３ａがｈｓａ－ｍｉＲ－６６３ａであり、ｍｉＲ－４５１３がｈｓａ－ｍｉＲ－４５１３であり、ｍｉＲ－６７８１－５ｐがｈｓａ－ｍｉＲ－６７８１－５ｐであり、ｍｉＲ－１２２７－５ｐがｈｓａ－ｍｉＲ－１２２７－５ｐであり、ｍｉＲ－６８４５－５ｐがｈｓａ－ｍｉＲ－６８４５－５ｐであり、ｍｉＲ－６７９８－５ｐがｈｓａ－ｍｉＲ－６７９８－５ｐであり、ｍｉＲ－３６２０－５ｐがｈｓａ－ｍｉＲ－３６２０－５ｐであり、ｍｉＲ－１９１５－５ｐがｈｓａ－ｍｉＲ－１９１５－５ｐであり、ｍｉＲ－４２９４がｈｓａ－ｍｉＲ－４２９４であり、ｍｉＲ－６４２ａ－３ｐがｈｓａ－ｍｉＲ－６４２ａ－３ｐであり、ｍｉＲ－３７１ａ－５ｐがｈｓａ－ｍｉＲ－３７１ａ－５ｐであり、ｍｉＲ－９４０がｈｓａ－ｍｉＲ－９４０であり、ｍｉＲ－４４５０がｈｓａ－ｍｉＲ－４４５０であり、ｍｉＲ－４７２３－５ｐがｈｓａ－ｍｉＲ－４７２３－５ｐであり、ｍｉＲ－１４６９がｈｓａ－ｍｉＲ－１４６９であり、ｍｉＲ－６８６１－５ｐがｈｓａ－ｍｉＲ－６８６１－５ｐであり、ｍｉＲ－７９７５がｈｓａ－ｍｉＲ－７９７５であり、ｍｉＲ－６８７９－５ｐがｈｓａ－ｍｉＲ－６８７９－５ｐであり、ｍｉＲ－６８０２－５ｐがｈｓａ－ｍｉＲ－６８０２－５ｐであり、ｍｉＲ－１２６８ｂがｈｓａ－ｍｉＲ－１２６８ｂであり、ｍｉＲ－６６３ｂがｈｓａ－ｍｉＲ－６６３ｂであり、ｍｉＲ－１２５ａ－３ｐがｈｓａ－ｍｉＲ－１２５ａ－３ｐであり、ｍｉＲ－２８６１がｈｓａ－ｍｉＲ－２８６１であり、ｍｉＲ－６０８８がｈｓａ－ｍｉＲ－６０８８であり、ｍｉＲ－４７５８－５ｐがｈｓａ－ｍｉＲ－４７５８－５ｐであり、ｍｉＲ－２９６－３ｐがｈｓａ－ｍｉＲ－２９６－３ｐであり、ｍｉＲ－６７３８－５ｐがｈｓａ－ｍｉＲ－６７３８－５ｐであり、ｍｉＲ－６７１－５ｐがｈｓａ－ｍｉＲ－６７１－５ｐであり、ｍｉＲ－４４５４がｈｓａ－ｍｉＲ－４４５４であり、ｍｉＲ－４５１６がｈｓａ－ｍｉＲ－４５１６であり、ｍｉＲ－７８４５－５ｐがｈｓａ－ｍｉＲ－７８４５－５ｐであり、ｍｉＲ－４７４１がｈｓａ－ｍｉＲ－４７４１であり、ｍｉＲ－９２ｂ－５ｐがｈｓａ－ｍｉＲ－９２ｂ－５ｐであり、ｍｉＲ－６７９５－５ｐがｈｓａ－ｍｉＲ－６７９５－５ｐであり、ｍｉＲ－６８０５－３ｐがｈｓａ－ｍｉＲ－６８０５－３ｐであり、ｍｉＲ－４７２５－３ｐがｈｓａ－ｍｉＲ－４７２５－３ｐであり、ｍｉＲ－６７８２－５ｐがｈｓａ－ｍｉＲ－６７８２－５ｐであり、ｍｉＲ－４６８８がｈｓａ－ｍｉＲ－４６８８であり、ｍｉＲ－６８５０－５ｐがｈｓａ－ｍｉＲ－６８５０－５ｐであり、ｍｉＲ－６７７７－５ｐがｈｓａ－ｍｉＲ－６７７７－５ｐであり、ｍｉＲ－６７８５－５ｐがｈｓａ－ｍｉＲ－６７８５－５ｐであり、ｍｉＲ－７１０６－５ｐがｈｓａ－ｍｉＲ－７１０６－５ｐであり、ｍｉＲ－３６６３－３ｐがｈｓａ－ｍｉＲ－３６６３－３ｐであり、ｍｉＲ－６１３１がｈｓａ－ｍｉＲ－６１３１であり、ｍｉＲ－１９１５－３ｐがｈｓａ－ｍｉＲ－１９１５－３ｐであり、ｍｉＲ－４５３２がｈｓａ－ｍｉＲ－４５３２であり、ｍｉＲ－６８２０－５ｐがｈｓａ－ｍｉＲ－６８２０－５ｐであり、ｍｉＲ－４６８９がｈｓａ－ｍｉＲ－４６８９であり、ｍｉＲ－４６３８－５ｐがｈｓａ－ｍｉＲ－４６３８－５ｐであり、ｍｉＲ－３６５６がｈｓａ－ｍｉＲ－３６５６であり、ｍｉＲ－３６２１がｈｓａ－ｍｉＲ－３６２１であり、ｍｉＲ－６７６９ｂ－５ｐがｈｓａ－ｍｉＲ－６７６９ｂ－５ｐであり、ｍｉＲ－１４９－３ｐがｈｓａ－ｍｉＲ－１４９－３ｐであり、ｍｉＲ－２３ｂ－３ｐがｈｓａ－ｍｉＲ－２３ｂ－３ｐであり、ｍｉＲ－３１３５ｂがｈｓａ－ｍｉＲ－３１３５ｂであり、ｍｉＲ－６８４８－５ｐがｈｓａ－ｍｉＲ－６８４８－５ｐであり、ｍｉＲ－６７６９ａ－５ｐがｈｓａ－ｍｉＲ－６７６９ａ－５ｐであり、ｍｉＲ－４３２７がｈｓａ－ｍｉＲ－４３２７であり、ｍｉＲ－６７６５－３ｐがｈｓａ－ｍｉＲ－６７６５－３ｐであり、ｍｉＲ－６７１６－５ｐがｈｓａ－ｍｉＲ－６７１６－５ｐであり、ｍｉＲ－６８７７－５ｐがｈｓａ－ｍｉＲ－６８７７－５ｐであり、ｍｉＲ－６７２７－５ｐがｈｓａ－ｍｉＲ－６７２７－５ｐであり、ｍｉＲ－４５３４がｈｓａ－ｍｉＲ－４５３４であり、ｍｉＲ－６１４がｈｓａ－ｍｉＲ－６１４であり、ｍｉＲ－１２０２がｈｓａ－ｍｉＲ－１２０２であり、ｍｉＲ－５７５がｈｓａ－ｍｉＲ－５７５であり、ｍｉＲ－６８７０－５ｐがｈｓａ－ｍｉＲ－６８７０－５ｐであり、ｍｉＲ－６７２２－３ｐがｈｓａ－ｍｉＲ－６７２２－３ｐであり、ｍｉＲ－７９７７がｈｓａ－ｍｉＲ－７９７７であり、ｍｉＲ－４６４９－５ｐがｈｓａ－ｍｉＲ－４６４９－５ｐであり、ｍｉＲ－４６７５がｈｓａ－ｍｉＲ－４６７５であり、ｍｉＲ－６０７５がｈｓａ－ｍｉＲ－６０７５であり、ｍｉＲ－６７７９－５ｐがｈｓａ－ｍｉＲ－６７７９－５ｐであり、ｍｉＲ－４２７１がｈｓａ－ｍｉＲ－４２７１であり、ｍｉＲ－３１９６がｈｓａ－ｍｉＲ－３１９６であり、ｍｉＲ－６８０３－５ｐがｈｓａ－ｍｉＲ－６８０３－５ｐであり、ｍｉＲ－６７８９－５ｐがｈｓａ－ｍｉＲ－６７８９－５ｐであり、ｍｉＲ－４６４８がｈｓａ－ｍｉＲ－４６４８であり、ｍｉＲ－４５０８がｈｓａ－ｍｉＲ－４５０８であり、ｍｉＲ－４７４９－５ｐがｈｓａ－ｍｉＲ－４７４９－５ｐであり、ｍｉＲ－４５０５がｈｓａ－ｍｉＲ－４５０５であり、ｍｉＲ－５６９８がｈｓａ－ｍｉＲ－５６９８であり、ｍｉＲ－１１９９－５ｐがｈｓａ－ｍｉＲ－１１９９－５ｐであり、ｍｉＲ－４７６３－３ｐがｈｓａ－ｍｉＲ－４７６３－３ｐであり、ｍｉＲ－６８３６－３ｐがｈｓａ－ｍｉＲ－６８３６－３ｐであり、ｍｉＲ－３１９５がｈｓａ－ｍｉＲ－３１９５であり、ｍｉＲ－７１８がｈｓａ－ｍｉＲ－７１８であり、ｍｉＲ－３１７８がｈｓａ－ｍｉＲ－３１７８であり、ｍｉＲ－６３８がｈｓａ－ｍｉＲ－６３８であり、ｍｉＲ－４４９７がｈｓａ－ｍｉＲ－４４９７であり、ｍｉＲ－６０８５がｈｓａ－ｍｉＲ－６０８５であり、ｍｉＲ－６７５２－５ｐがｈｓａ－ｍｉＲ－６７５２－５ｐであり、及び、ｍｉＲ－
in hsa-miR-135a-3p 135a-3p (1) on the kit provided.

[0023]

(3) wherein nucleic acid is below (a)-(e) the polynucleotide indicates:
(a) 1-171 and 606-nucleotide sequence that is represented by one or more of the 614 polynucleotide composed of u t in the nucleotide sequence or array, the mutants, derivatives, or 15 or more consecutive bases, including their fragments,
(b) 1-171 and 606-polynucleotide containing a nucleotide sequence that is represented by one or more of the 614
(c) 1-171 and 606-nucleotide sequence that is represented by one or more of the 614 array or u t in the nucleotide sequences phase polynucleotide comprising a nucleotide sequence complementary, the mutants, derivatives, or 15 or more consecutive bases, including their fragments,
(d) 1-171 and 606-nucleotide sequence that is represented by one or more of the 614 array or u t in the nucleotide sequences phase polynucleotide containing complementary sequences, and
(e) subparagraph (a) to (d) or polynucleotides and polynucleotide hybridized under stringent conditions,
From a polynucleotide selected from the group in the to (1) or (2) of Kit.

[0024]

(4) wherein Kit's, colon cancer polynucleotide selected from the group consisting of miR-1231, miR-1233-5p, miR-150-3p, miR-1225-3p, miR-92a-2-5p, miR-423-5p, miR-1268 a, miR-128-2-5p and miR-24-3p in the marker at least one more and that can be merged into specific nucleic acids in addition, including (1)-(3) or in Kit.

[0025]

(5) miR-1231 is hsa-miR-1231 and miR-1233-5p is a hsa-miR-1233-5p, miR-150-3p is hsa-miR-150-3p and, miR-1225-3p is a hsa-miR-1225-3p, miR-92a-2-5p is hsa-miR-92a-2-5p and, miR-423-5p is a hsa-miR-423-5p, miR-1268 a hsa-miR-1268 a, miR-128-2-5p is a hsa-miR-128-2-5p and miR-24-3p in hsa-miR-24-3p, (4) the kit mentioned.

[0026]

(6) said nucleic acid is below (f) to (j) to polynucleotides that:
(f) an array number 172-base is represented by one or more of the 180 that piece of polynucleotide arrays or from u t in the nucleotide sequences, the mutants, derivatives, or 15 or more consecutive bases, including the
(g) an array number 172-polynucleotide containing a nucleotide sequence that is represented by one or more of the 180
(h) an array number 172-base is represented by one or more of the 180 array or u t in the nucleotide sequences phase polynucleotide comprising a nucleotide sequence complementary, the mutants, derivatives, or 15 or more consecutive bases, including their fragments,
(i) an array number 172-base is represented by one or more of the 180 array or u t in the nucleotide sequences phase polynucleotide containing a nucleotide complementary and
(j) above (f) to (I) either polynucleotides and polynucleotide hybridized under stringent conditions,
From a polynucleotide selected from the group in the to (4) or (5) of Kit.

[0027]

(7) colon cancer kits wherein the, polynucleotide selected from the group consisting of miR-4697-5p, miR-3197, miR-675-5p, miR-4486, miR-7107-5p, miR-23a-3p, miR-4667-5p, miR-451 a, miR-3940-5p, miR-8059, miR-6813-5p, miR-4492, miR-4476 and miR-6090 in the marker at least one more and that can be merged into specific nucleic acid containing more (1) to (6) or in Kit.

[0028]

(8) miR-4697-5p is hsa-miR-4697-5p and miR-3197 is hsa-miR-3197 and miR-675-5p is a hsa-miR-675-5p, miR-4486 is hsa-miR-4486, miR-7107-5p is a hsa-miR-7107-5p, miR-23a-3p is a hsa-miR-23a-3p, miR-4667-5p is hsa-miR-4667-5p, and miR-451 a hsa-miR-451 a, is miR-3940-5p and hsa-miR-3940-5p, miR-8059 is hsa-miR-8059 and, miR-6813-5p is a hsa-miR-6813-5p, is miR-4492 and hsa-miR-4492, is miR-4476 and hsa-miR-4476, and, miR-6090 is hsa-miR-6090, (7) to the kit provided.